Intranasal Ketamine Dosing for Adults
For acute pain management in adults, intranasal ketamine should be administered at approximately 1 mg/kg (range 0.5-1.0 mg/kg), with a maximum single dose not exceeding 50 mg, and may be repeated after 15-30 minutes if inadequate pain relief is achieved. 1, 2
Weight-Based Dosing Guidelines
Standard Dosing Ranges
- Initial dose: 0.5-1.0 mg/kg intranasally 1, 2
- Optimal effective dose: Approximately 1 mg/kg appears most effective, with 56% of patients achieving clinically significant pain reduction (≥20 mm on visual analog scale) at this dose 1
- Maximum single dose: 50 mg 3
- Repeat dosing: If pain persists after 15 minutes, an additional 0.5 mg/kg may be administered 1
Dose-Response Relationship for Pain
For cancer-related pain, a dose-escalation study demonstrated:
- 10 mg intranasal: Median pain reduction of 1.5 points (22.5% maximal pain relief) 3
- 30 mg intranasal: Median pain reduction of 3 points (65.5% maximal pain relief) 3
- 50 mg intranasal: Median pain reduction of 4 points (69.25% maximal pain relief) with best tolerability profile 3
Neuropathic Pain Dosing
For neuropathic pain, lower doses may be effective:
- 0.2 mg/kg (approximately 14-20 mg for average adult): Achieved peak plasma concentrations of 27.7 ng/mL with 70% pain reduction 4
- 0.4 mg/kg (approximately 28-40 mg for average adult): Achieved peak plasma concentrations of 34.3 ng/mL with 61% pain reduction 4
Psychiatric Indications
Depression and Suicidality
For acute suicidality or treatment-resistant depression:
- Fixed dose: 75 mg intranasal racemic ketamine as single administration 5
- Note: This is higher than analgesic dosing and requires psychiatric supervision with structured safety monitoring 5, 6
Pharmacokinetic Considerations
Time to Effect and Duration
- Peak plasma concentration: Achieved at 10-14 minutes post-administration 4
- Onset of analgesia: Median 9.5 minutes (range 5-25 minutes) 2
- Duration of effect: Significant pain reduction maintained for 60-240 minutes 1, 3
- Metabolite formation: (S)-norketamine peaks at 75-81 minutes and correlates with sustained analgesia 4
Safety Parameters and Monitoring
Maximum Dosing Limits
- Single procedure maximum: Do not exceed 50 mg per administration for pain management 3
- Weight-based ceiling: Doses above 6 mg/kg are associated with increased adverse effects 7
- Daily maximum: For repeated dosing, total daily dose should not exceed 300 mg 7
Common Adverse Effects
Transient side effects occur in a dose-dependent manner 2, 3:
- Dizziness: 53% of patients 2
- Feeling of unreality/dissociation: 35% 2
- Nausea: 10% 2
- All adverse effects typically resolve within the study visit period (≤4 hours) without intervention 2, 3
Clinical Pitfalls and Contraindications
Important Caveats
- Avoid in patients with: Uncontrolled hypertension, active coronary artery disease, or increased intracranial pressure (extrapolated from IV ketamine guidelines) 8
- Abuse potential: One case of ketamine misuse was reported several weeks after intranasal administration for suicidality, highlighting the need for careful patient selection and follow-up 5
- Bioavailability: Intranasal ketamine has approximately 45-50% bioavailability compared to IV administration, necessitating higher absolute doses 9
Monitoring Requirements
- Vital signs: Monitor blood pressure, heart rate, and oxygen saturation for at least 60 minutes post-administration 3
- Dissociative symptoms: Use structured assessment tools (e.g., CADSS) when treating psychiatric conditions 5
- Minimize stimulation: Reduce environmental stimuli during recovery period to decrease emergence reactions 10
Route Comparison Context
While intranasal administration is convenient and non-invasive, IV ketamine at 0.5 mg/kg over 40 minutes remains the gold standard for depression treatment based on the most robust evidence 11, 12. However, intranasal administration offers practical advantages for acute pain management in emergency settings where IV access may be delayed 1, 2.